Grifols (GRF) CMD 2025 summary

Strategic vision and growth targets

• Aims to achieve €10 billion revenue by 2029 and €14 billion by 2034, doubling size over the next decade, driven by biopharma growth, innovation, and operational efficiency.

• Projects EBITDA of €2.9 billion with a 29–30% margin and €1.2 billion free cash flow by 2029, targeting a 40% cash conversion rate.

• Strategic plan is bottom-up, realistic, and organization-wide, with a 7% revenue CAGR and 10% EBITDA CAGR from 2024–2029.

• Focuses on disciplined capital allocation, prioritizing organic investment, cost control, and margin expansion, with dividends to resume in 2025.

• Biopharma is the primary growth driver, with diagnostics expected to accelerate in later years and a vision for global patient access and sustainability.

Financial performance and guidance

• 2024 delivered record revenues (€7.2 billion, +10.3% cc) and EBITDA (+21% adj., +32% reported), with strong free cash flow outperformance.

• 2025 guidance: €7.7 billion revenue, €2.025 billion adjusted EBITDA, and €500 million free cash flow pre-M&A, with IRA Part D redesign impact of €100–150 million fully embedded.

• Leverage reduced from 6.8x to 4.6x in 2024, targeting 3.0–3.5x by 2029, with significant organic deleveraging planned.

• Cumulative free cash flow generation pre-M&A projected at €3.5–3.75 billion over 2025–2029.

• Dividend policy to be reinstated from 2025, with potential for share buybacks as balance sheet strengthens.

Value creation plan, operational improvements, and margin expansion

• Value creation driven by commercial growth (IG, Albumin, Alpha-1, new launches), margin expansion (plasma sourcing, collection excellence, yield improvements), and pipeline execution.

• Achieved over €450 million in savings through operational improvements, optimizing cost and cash flow.

• Margin expansion supported by cost per liter reduction, individualized nomogram rollout, and yield optimization, aiming for a 500 bps EBITDA margin increase by 2029.

• CapEx needs are well-defined, with €2.5 billion planned over five years, declining as a percentage of revenue.

• Commitment to digitalization and innovation across R&D and commercialization to drive continuous improvement.